Pharmacokinetic Profiles of Ceftazidime in Cochlear Perilymph, Cerebrospinal Fluid and Plasma: A High-Performance Liquid Chromatographic Study

ORL ◽  
1995 ◽  
Vol 57 (5) ◽  
pp. 256-259 ◽  
Author(s):  
Ai-Hua Sun ◽  
Lome S. Parnes ◽  
David J. Freeman
Keyword(s):  
Cerebrospinal Fluid ◽  
High Performance ◽  
High Performance Liquid Chromatographic ◽  
Chromatographic Study ◽  
Pharmacokinetic Profiles ◽  
Liquid Chromatographic

Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

1984 ◽  
Vol 2 (5) ◽  
pp. 432-437 ◽  
Author(s):  
U Tirelli ◽  
M D'Incalci ◽  
R Canetta ◽  
S Tumolo ◽  
G Franchin ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Median Survival ◽  
Stable Disease ◽  
High Performance ◽  
Clinical Symptoms ◽  
Early Death ◽  
High Performance Liquid Chromatographic ◽  
Malignant Brain Tumors ◽  
Liquid Chromatographic

Twenty-two consecutive patients with recurrent malignant brain tumors after radiation therapy and systemic combination chemotherapy with BCNU and vincristine, four of whom were not evaluable due to early death, were treated with etoposide (VP-16-213) (50-100 mg/m2 for five days every three weeks). Response, defined as improvement in both clinical examination and computed tomography scan in absence of glucocorticoids dosage increase, was observed in three (17%) of 18 evaluable patients, lasting greater than 21, seven, and two months, respectively. Six additional patients had stable disease for greater than 10, seven, four, four, three, and two months: all of them had improvement of clinical symptoms but no variation in their scans. Overall median survival from the start of VP-16-213 was 4.5 months (range, 1-23 + months), whereas patients with response or stable disease had a median survival of eight months. Overall, treatment was well tolerated. In 10 patients concomitant plasma and cerebrospinal fluid samples were evaluated with a high-performance liquid chromatographic method for drug assay. The concentration of VP-16-213 in cerebrospinal fluid was less than 1% that found in plasma, even in the two patients with response. The activity of etoposide in patients with malignant, lomustine-vincristine-resistant brain tumors suggests an interesting potential use for this drug.

Sign in / Sign up

Export Citation Format

Share Document